{
    "Trade/Device Name(s)": [
        "QMS Lamotrigine",
        "QMS\u00ae Lamotrigine"
    ],
    "Submitter Information": "Seradyn, Inc",
    "510(k) Number": "K062966",
    "Predicate Device Reference 510(k) Number(s)": [
        "K051211"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "ORH",
        "LAS",
        "DLJ"
    ],
    "Summary Letter Date": "December 20, 2006",
    "Summary Letter Received Date": "December 21, 2006",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.3350"
    ],
    "Regulation Name(s)": [
        "Diphenylhydantoin Test System"
    ],
    "Analyte Class(es)": [
        "tdm",
        "toxicology"
    ],
    "Analyte(s)": [
        "Lamotrigine"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Automated clinical chemistry analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous particle-enhanced turbidimetric immunoassay",
        "Particle agglutination"
    ],
    "Methodologies": [
        "Competitive binding assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for QMS Lamotrigine homogeneous particle-enhanced turbidimetric immunoassay for measuring lamotrigine in serum or plasma.",
    "Indications for Use Summary": "Intended for quantitative determination of lamotrigine in human serum or plasma as an aid in management of patients treated with lamotrigine, using automated clinical chemistry analyzers.",
    "fda_folder": "Toxicology"
}